RASi pharmacotherapy (Angiotensin Receptor Blockers [ARBs] or Angiotensin Converting Enzyme inhibitors [ACEi]) was used by 44% of the cohort, with 50% in the diagnosed CKD group, 28% in the proxy-diagnosed group, and 47% in the undiagnosed group. The gene discussed is ACE; the disease is chronic kidney disease.